News

Eli Lilly: A Textbook Insider Buying Play

Buy-rated stock with attractive valuation and strong growth in weight loss sales. Insider buys signal confidence; key FDA ...
Medical Dialogues6h

Superluminal Medicines, Eli Lilly forge USD 1.3 billion alliance to advance Small Molecule Therapeutics

Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...

Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly: Don't Bet Against This Biotech Powerhouse

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

Texas sues, accusing Eli Lilly of 'bribing' physicians to prescribe Zepbound, Mounjaro and other drugs

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Eli Lilly and Company (LLY) Announces Results From LTE of Phase 3 TRAILBLAZER-ALZ 2 Study

To provide a brief background, the TRAILBLAZER-ALZ 2 LTE study was a Phase 3, double-blind extension of the original ...
TipRanks on MSN16h

Eli Lilly downgraded to Neutral from Outperform at Daiwa

Daiwa analyst Narumi Nakagiri downgraded Eli Lilly (LLY) to Neutral from Outperform with a $700 price target Published first on TheFly – the ...